Seven IPOs and one SPAC plan to raise $2.3 billion in the week ahead. While Casper Sleep's (CSPR) IPO down round creates more buzz about unprofitable unicorns, institutional investors are quietly eyeing drug development services provider PPD (PPD), set to be the year's second billion-dollar deal. They are joined by a life sciences tech company, a biotech, a REIT, a bank, and a boat retailer.
Casper plans to raise $150 million at a $734 million market cap. Like many unicorns before it, the company is fast-growing and unprofitable (-19% LTM EBITDA margin), but its IPO